Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.
Chen LY, Shah R, Cwynarski K, Lambert J, McNamara C, Mohamedbhai SG, Virchis A, Townsend W, D'Sa S, Ardeshna KM.
Chen LY, et al. Among authors: ardeshna km.
Br J Haematol. 2019 Feb;184(3):462-465. doi: 10.1111/bjh.15110. Epub 2018 Jan 24.
Br J Haematol. 2019.
PMID: 29363752
Free article.
No abstract available.